We are live on ! Find out more
ETC

Exchange Traded Concepts Portfolio holdings

AUM $21.9B
1-Year Est. Return 68.6%
This Fund
S&P 500
This Quarter Est. Return
+14.78%
1 Year Est. Return
+68.6%
3 Year Est. Return
+158.93%
5 Year Est. Return
+186.62%
10 Year Est. Return
AUM
$3.74B
AUM Growth
+$210M
Cap. Flow
-$188M
Cap. Flow %
-5.03%
Top 10 Hldgs %
16.39%
Holding
1,456
New
147
Increased
521
Reduced
429
Closed
232

Sector Composition

Rank Sector Weight
1 Technology 24.13%
2 Energy 12.45%
3 Healthcare 10.2%
4 Communication Services 6.83%
5 Industrials 6.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACLX
776
DELISTED
Arcellx
ACLX
$235K 0.01%
4,241
+1,076
+34% +$48.5K
ETN icon
777
Eaton
ETN
$141B
$235K 0.01%
975
+711
+269% +$157K
HE icon
778
Hawaiian Electric Industries
HE
$2.26B
$229K 0.01%
16,155
MRSN
779
DELISTED
Mersana Therapeutics
MRSN
$229K 0.01%
3,949
+1,001
+34% +$40.3K
MRSH
780
Marsh
MRSH
$94.3B
$222K 0.01%
1,172
-8,747
-88% -$1.69M
UDR icon
781
UDR
UDR
$12.9B
$219K 0.01%
5,732
-570
-9% -$19.8K
NUVL
782
DELISTED
Nuvalent
NUVL
$218K 0.01%
2,960
+750
+34% +$46.4K
IOVA icon
783
Iovance Biotherapeutics
IOVA
$2.04B
$216K 0.01%
26,603
+6,746
+34% +$35.3K
ZYME icon
784
Zymeworks
ZYME
$1.62B
$214K 0.01%
20,617
+5,228
+34% +$41.7K
ERII icon
785
Energy Recovery
ERII
$420M
$211K 0.01%
11,183
-406
-4% -$7.54K
PAGS icon
786
PagSeguro Digital
PAGS
$2.67B
$206K 0.01%
16,523
-1,193
-7% -$11K
RAIN
787
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$205K 0.01%
170,554
+43,248
+34% +$46.7K
KURA icon
788
Kura Oncology
KURA
$793M
$204K 0.01%
14,175
+3,594
+34% +$35.3K
THRX
789
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$196K 0.01%
48,510
+12,300
+34% +$37.5K
SMMT icon
790
Summit Therapeutics
SMMT
$10.2B
$196K 0.01%
74,971
+19,011
+34% +$39.1K
SWTX
791
DELISTED
SpringWorks Therapeutics
SWTX
$194K 0.01%
5,323
+1,350
+34% +$35.2K
YMAB
792
DELISTED
Y-mAbs Therapeutics
YMAB
$192K 0.01%
28,095
+7,124
+34% +$41.2K
GGG icon
793
Graco
GGG
$13.2B
$191K 0.01%
2,204
+44
+2% +$3.46K
PRLD icon
794
Prelude Therapeutics
PRLD
$375M
$188K 0.01%
44,087
+11,180
+34% +$34K
KYMR icon
795
Kymera Therapeutics
KYMR
$8.66B
$187K 0.01%
7,359
+1,866
+34% +$33.4K
LIN icon
796
Linde
LIN
$236B
$187K 0.01%
457
-18,648
-98% -$7.35M
REG icon
797
Regency Centers
REG
$14.9B
$184K ﹤0.01%
2,743
+801
+41% +$49.5K
IMCR icon
798
Immunocore
IMCR
$1.7B
$181K ﹤0.01%
2,656
+674
+34% +$35K
NDAQ icon
799
Nasdaq
NDAQ
$53.4B
$179K ﹤0.01%
3,077
+2,883
+1,486% +$152K
RAPT
800
DELISTED
RAPT Therapeutics
RAPT
$179K ﹤0.01%
899
+228
+34% +$28.2K

Similar funds

Exchange Traded Concepts's Q4 2023 Portfolio in Review

As of Q4 2023, Exchange Traded Concepts held 1,456 positions worth $3.74B, up 5.9% from $3.53B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Exchange Traded Concepts withdrew a net $188M in Q4 2023, closing 232 positions and reducing 429 holdings. Its most notable exit was iShares 0-3 Month Treasury Bond ETF, an estimated $366M position sold in full.

By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 21% a quarter earlier, followed by Energy and Healthcare.

Against the trend, Exchange Traded Concepts opened a new position in State Street Utilities Select Sector SPDR ETF worth $63M.

  • Exchange Traded Concepts's largest Q4 2023 buy was State Street Utilities Select Sector SPDR ETF: 1,990,668 shares worth $63M.
  • Exchange Traded Concepts added most to Vanguard Real Estate ETF in Q4 2023, an estimated $91.9M increase.
  • Exchange Traded Concepts's biggest Q4 2023 reduction was Vanguard Energy ETF, cutting an estimated $21.6M.
  • Exchange Traded Concepts fully exited iShares 0-3 Month Treasury Bond ETF in Q4 2023, selling an estimated $366M.
  • Exchange Traded Concepts's ten largest holdings make up 16% of its $3.74B portfolio in Q4 2023.
  • Exchange Traded Concepts opened 147 new positions and closed 232 in Q4 2023.
  • Exchange Traded Concepts's portfolio value rose 5.9% quarter-over-quarter to $3.74B.

Based on Exchange Traded Concepts's 13F filing for Q4 2023, filed 5 Jan 2024.